On this basis, we determined the immunoreactivity of NOTCH1 and PAX5 by immunohistochemistry, which can be used to analyze the variable expression of NOTCH1 and PAX5 in RSCs of pediatric patients diagnosed with cHL and positive for EBV infection. This evidence concerns the gene PAX5 and classic Hodgkin lymphoma.